Canaccord Genuity Reiterates a 'Buy' on Meridian Biosciences (VIVO); Positive Meeting With Management
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $4.36 +3.56%
Rating Summary:
3 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Meridian Biosciences (NASDAQ: VIVO) price target of $25.00.
Analyst, Jeffrey Frelick, said, "We reiterate our rating on VIVO shares following time spent traveling with management, as the company’s continued traction with Illumigene provides support for a return to sequential growth...We believe VIVO is once again poised to deliver sequential revenue growth as Illumigene continues to ramp. This is similar to 2003-2007 when Meridian benefitted from the conversion to its single test rapid assays from 96-well EIA tests, as pricing improved 2-3 times. The same is unfolding for conversion to MDx."
For an analyst ratings summary and ratings history on Meridian Biosciences click here. For more ratings news on Meridian Biosciences click here.
Shares of Meridian Biosciences closed at $18.36 yesterday.
Analyst, Jeffrey Frelick, said, "We reiterate our rating on VIVO shares following time spent traveling with management, as the company’s continued traction with Illumigene provides support for a return to sequential growth...We believe VIVO is once again poised to deliver sequential revenue growth as Illumigene continues to ramp. This is similar to 2003-2007 when Meridian benefitted from the conversion to its single test rapid assays from 96-well EIA tests, as pricing improved 2-3 times. The same is unfolding for conversion to MDx."
For an analyst ratings summary and ratings history on Meridian Biosciences click here. For more ratings news on Meridian Biosciences click here.
Shares of Meridian Biosciences closed at $18.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VivoPower plans separate listing for 2.2GW non-Nordic AI platform
- Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
- Clear Street Reiterates Buy Rating on Anterix Inc. (ATEX)
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
